Collegium Pharma (COLL) Tops Q3 EPS by 37c ; Offers Guidance

Collegium Pharma (NASDAQ: COLL) reported Q3 EPS of $2.25, $0.37 better than the analyst estimate of $1.88. Revenue for the quarter came in at $209.36 million versus the consensus estimate of $190.12 million.

GUIDANCE:

Collegium Pharma sees FY2025 revenue of $775-785 million, versus the consensus of $751.6 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Is Treasury selloff a major issue for stock market bulls?
• BofA sees dollar weakness continuing with New Zealand dollar gains